Valeritas (OTCMKTS:VLRXQ) versus Beyond Air (NASDAQ:XAIR) Head-To-Head Analysis

Beyond Air (NASDAQ:XAIR) and Valeritas (OTCMKTS:VLRXQ) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Beyond Air and Valeritas, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beyond Air	0	1	3	1	3.00
Valeritas	0	0	0	0	0.00

Beyond Air presently has a consensus price target of $3.67, suggesting a potential upside of 1,194.27%. Given Beyond Air’s stronger consensus rating and higher probable upside, research analysts clearly believe Beyond Air is more favorable than Valeritas.

Profitability

This table compares Beyond Air and Valeritas’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Beyond Air	-1,730.00%	-226.01%	-109.75%
Valeritas	N/A	N/A	N/A

Valuation & Earnings

This table compares Beyond Air and Valeritas”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beyond Air	$3.02 million	6.45	-$60.24 million	($1.06)	-0.27
Valeritas	N/A	N/A	N/A	N/A	N/A

Valeritas has lower revenue, but higher earnings than Beyond Air.

Insider & Institutional Ownership

31.5% of Beyond Air shares are owned by institutional investors. 20.1% of Beyond Air shares are owned by company insiders. Comparatively, 1.0% of Valeritas shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Beyond Air beats Valeritas on 7 of the 10 factors compared between the two stocks.

About Beyond Air

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

About Valeritas

Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.